SB

Sagimet Biosciences Inc.

SGMT·NASDAQ

$6.86

+1.3%
HealthcareBiotechnology

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

At a Glance

Live Snapshot
Market Cap$223.51M
EPS-1.5800
P/E Ratio-4.34
Earnings Date08/12/2026

sgmt

Short Term Investments

Last Annual Value

78.10M

3-Year CAGR

34%

5-Year CAGR

%

10-Year CAGR

%

SB

Sagimet Biosciences Inc. Competitors Analysis of Short Term Investments

SGMT · NASDAQ
CompanyShort Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
78.10M
58.1%N/AN/A 
131.15M
-6.8%54.1%-0.5%
206.12M
-22.0%N/AN/A
189.66M
19.8%13.4%22.8%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
0.00
N/AN/AN/A
126.98M
-23.0%-1.3%N/A
156.57M
-18.1%-3.5%-2.1%
0.00
N/AN/AN/A
0.00
N/AN/AN/A
78.02M
-20.2%8.0%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
0.00
N/AN/AN/A
SB

Sagimet Biosciences Inc. Fair Value Envelope

SGMT · NASDAQ

Our analysis suggests that SGMT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.86, this represents a potential HIDDEN relative to our calculated worth for Sagimet Biosciences Inc..

Intrinsic Value
Current Price: $6.86